SLDB

Over the past six months (March 2026 to September 2026), Solid Biosciences experienced several stock-impacting events. In March 2026, the company reported positive interim data for SGT-003, announced plans for its Phase 3 trial, reported first participant dosing for SGT-212, activated clinical sites for SGT-501, and renamed its AAV-SLB101 capsid platform to POLARIS-101™. In April 2026, SGT-003 received Orphan Drug designation from the European Commission. May 2026 saw the company report first-quarter financial results, indicating a cash runway into the first half of 2028. In June 2026, a co-marketing collaboration with NanoMosaic for its POLARIS-101 capsid technology was announced. August 2026 brought second-quarter financial results, extending the cash runway into mid-2028, with updates on SGT-003's tolerability and trial progress, SGT-212's safety, and targeted first dosing for SGT-501 in the second half of 2026, alongside plans for an FDA meeting. In September 2026, the company participated in investor conferences, and multiple analysts initiated or reiterated positive ratings. Overall, Solid Biosciences' stock price increased by 58.2% from the start of 2026 to September 22, 2026.